Anaveon is a clinical stage biotech company with a focus on the engineering and development of cytokines to create and develop novel safe and effective treatments for cancer and immune-mediated diseases. Our lead program, ANV419, is a powerful and selective “non-alpha” IL-2 receptor agonist for the treatment of cancer. ANV419 is an engineered IL-2 fusion to an antibody that signals selectively through the beta/gamma dimeric IL-2 receptor and stimulates the proliferation of CD8 T cells and NK cells while avoiding the proliferation of immunosuppressive regulatory T cells. With its unique signaling profile ANV419 has the potential to substantially separate desired anti-tumor responses from the dose-limiting toxicities observed with the existing recombinant IL-2 cancer therapeutic Aldesleukin. ANV419 is currently entering phase I clinical development for the immunotherapeutic treatment of tumors.